Literature DB >> 1964123

Adrenergic supersensitivity in parkinsonians with orthostatic hypotension.

J M Senard1, P Valet, G Durrieu, M Berlan, M A Tran, J L Montastruc, A Rascol, P Montastruc.   

Abstract

The adrenergic status was studied through evaluation of platelet alpha 2-adrenoceptor number [( 3H]yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P less than 0.05) decreased from 144 +/- 9 and 76 +/- 6 mmHg in the lying position to 95 +/- 12 and 60 +/- 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 +/- 11 pg ml-1, (P less than 0.05) when compared with controls (219 +/- 13 pg ml-1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 +/- 14 pg ml-1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P less than 0.01) lower in Parkinsonians with orthostatic hypotension (0.19 +/- 0.03 microgram kg-1) when compared with Parkinsonians without orthostatic hypotension (0.86 +/- 0.11 microgram kg-1) or with controls (0.68 +/- 0.1 microgram kg-1). Platelet alpha 2-adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 +/- 52 fmol mg-1 protein) than in Parkinsonians without orthostatic hypotension (168 +/- 9 fmol mg-1 protein) or in controls (175 +/- 4 fmol mg-1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet alpha 2-adrenoceptor number.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964123     DOI: 10.1111/j.1365-2362.1990.tb01909.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  29 in total

Review 1.  Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease.

Authors:  D S Goldstein
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

2.  Coronary vascular resistance in primary chronic autonomic failure.

Authors:  Sheng-Ting Li; Basil A Eldadah; Yehonatan Sharabi; Sandra Pechnik; David S Goldstein
Journal:  Clin Auton Res       Date:  2006-05-23       Impact factor: 4.435

3.  Pharmacological evidence of alpha 1- and alpha 2-adrenergic supersensitivity in orthostatic hypotension due to spinal cord injury: a case report.

Authors:  J M Senard; A Arias; M Berlan; M A Tran; A Rascol; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

5.  Temporal prolongation of decreased skin blood flow causes cold limbs in Parkinson's disease.

Authors:  Kazumasa Shindo; Fumikazu Kobayashi; Michiaki Miwa; Takamura Nagasaka; Yoshihisa Takiyama; Zenji Shiozawa
Journal:  J Neural Transm (Vienna)       Date:  2012-08-11       Impact factor: 3.575

Review 6.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 7.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

8.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

9.  Benefits of fludrocortisone in the treatment of symptomatic vasodepressor carotid sinus syndrome.

Authors:  D da Costa; S McIntosh; R A Kenny
Journal:  Br Heart J       Date:  1993-04

10.  Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.

Authors:  H Bagheri; P Picault; L Schmitt; G Houin; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.